Showing results (1-10 of 212) with videos related to
Sort By:
Pageof 22
Nature Biotechnology|September 10, 2005
Arming antibodies: prospects and challenges for immunoconjugatesAnna M Wu, Peter D SenterCurrent Opinion in Chemical Biology|May 6, 2009
Potent antibody drug conjugates for cancer therapyPeter D SenterHematology. American Society of Hematology. Education Program|December 10, 2013
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancerJonathan G Drachman, Peter D SenterCancer Journal (Sudbury, Mass.)|June 10, 2008
Antibody-drug conjugates for cancer therapyPaul J Carter, Peter D SenterNature Biotechnology|July 12, 2012
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaPeter D Senter, Eric L SieversAnnual Review of Medicine|October 10, 2012
Antibody-drug conjugates in cancer therapyEric L Sievers, Peter D SenterHematology/Oncology Clinics of North America|November 30, 2013
Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drugNicole M Okeley, Stephen C Alley, Peter D SenterMabs|January 15, 2010
Antibody drug-conjugates targeting the tumor vasculature: Current and future developmentsHans-Peter Gerber, Peter D Senter, Iqbal S GrewalCurrent Opinion in Chemical Biology|July 21, 2010
Antibody-drug conjugates: targeted drug delivery for cancerStephen C Alley, Nicole M Okeley, Peter D SenterACS Medicinal Chemistry Letters|June 6, 2014
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic AgentsScott C Jeffrey, Jef De Brabander, Jamie Miyamoto, et al.Pageof 22